Ailawadhi Sikander, Pafundi Deanna, Peterson Jennifer
Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.
Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Expert Rev Anticancer Ther. 2025 Apr;25(4):351-361. doi: 10.1080/14737140.2025.2472859. Epub 2025 Mar 3.
Targeted radiopharmaceutical therapies (RPTs) have emerged as a promising approach for the precise treatment of various cancers. Delivering ionizing radiation directly to cancer cells while sparing surrounding healthy tissue, radiopharmaceuticals offer enhanced efficacy and reduced toxicity compared to conventional external beam radiation therapy (i.e. photons and electrons).
In the current era of personalized cancer care, the appropriate choice of RPTs for a clinical condition and the specific patient's care needs to be better understood. Several available RPT agents with their respective clinical applicability along with rapidly ongoing research in this field have now given RPTs the ability to lend themselves to a personalized medicine focus. This review provides an overview of recent advancements in RPT, including nuclide selection and development, molecular targeting strategies, radiopharmaceutical development, and clinical applications.
We discuss the underlying principles, challenges, and opportunities for future development. Furthermore, we explore emerging technologies and future directions in the field, highlighting the potential impact on personalized cancer care.
靶向放射性药物疗法（RPTs）已成为一种有前景的精准治疗多种癌症的方法。放射性药物将电离辐射直接传递至癌细胞，同时保护周围健康组织，与传统外照射放疗（即光子和电子放疗）相比，具有更高的疗效和更低的毒性。
在当前个性化癌症治疗时代，需要更好地理解针对临床情况和特定患者护理需求的RPTs的合适选择。几种可用的RPT药物及其各自的临床适用性，以及该领域正在迅速开展的研究，现在使RPTs有能力专注于个性化医疗。本综述概述了RPT的最新进展，包括核素选择与开发、分子靶向策略、放射性药物开发和临床应用。
我们讨论了其潜在原理、挑战和未来发展机遇。此外，我们探索该领域的新兴技术和未来方向，强调其对个性化癌症治疗的潜在影响。
